Literature DB >> 12796524

Effects of levodopa on motor sequence learning in Parkinson's disease.

A Feigin1, M F Ghilardi, M Carbon, C Edwards, M Fukuda, V Dhawan, C Margouleff, C Ghez, D Eidelberg.   

Abstract

BACKGROUND: Dopaminergic therapy with levodopa improves motor function in PD patients, but the effects of levodopa on cognition in PD remain uncertain.
OBJECTIVE: To use H(2)(15)O and PET to assess the effect of levodopa infusion on motor sequence learning in PD.
METHODS: Seven right-handed PD patients were scanned "on" and "off" levodopa while performing a sequence learning task. The changes in learning performance and regional brain activation that occurred during this intervention were assessed.
RESULTS: During PET imaging, levodopa infusion reduced learning performance as measured by subject report (p < 0.05). This behavioral change was accompanied by enhanced activation during treatment in the right premotor cortex and a decline in the ipsilateral occipital association area (p < 0.01). Levodopa-induced changes in learning-related activation responses in the occipital association cortex correlated with changes in learning indexes (p < 0.01).
CONCLUSIONS: Levodopa treatment appears to have subtle detrimental effects on cognitive function in nondemented PD patients. These effects may be mediated through an impairment in brain activation in occipital association cortex.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12796524     DOI: 10.1212/01.wnl.0000072263.03608.42

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  34 in total

Review 1.  The assessment of neurological systems with functional imaging.

Authors:  David Eidelberg
Journal:  Brain Lang       Date:  2006-08-08       Impact factor: 2.381

2.  Assessment of disease progression in parkinsonism.

Authors:  Kotaro Asanuma; Vijay Dhawan; Maren Carbon; David Eidelberg
Journal:  J Neurol       Date:  2004-10       Impact factor: 4.849

Review 3.  Dopamine overdose hypothesis: evidence and clinical implications.

Authors:  David E Vaillancourt; Daniel Schonfeld; Youngbin Kwak; Nicolaas I Bohnen; Rachael Seidler
Journal:  Mov Disord       Date:  2013-10-09       Impact factor: 10.338

4.  Levodopa impairs probabilistic reversal learning in healthy young adults.

Authors:  Andrew Vo; Ken N Seergobin; Sarah A Morrow; Penny A MacDonald
Journal:  Psychopharmacology (Berl)       Date:  2016-05-30       Impact factor: 4.530

5.  The single intake of levodopa modulates implicit learning in drug naïve, de novo patients with idiopathic Parkinson's disease.

Authors:  Sarah Geffe; Katharina A Schindlbeck; Arne Mehl; Johann Jende; Fabian Klostermann; Frank Marzinzik
Journal:  J Neural Transm (Vienna)       Date:  2016-04-23       Impact factor: 3.575

6.  Dorsal striatum mediates deliberate decision making, not late-stage, stimulus-response learning.

Authors:  Nole M Hiebert; Adrian M Owen; Ken N Seergobin; Penny A MacDonald
Journal:  Hum Brain Mapp       Date:  2017-09-25       Impact factor: 5.038

7.  Can levodopa prevent cognitive decline in patients with Parkinson's disease?

Authors:  Masahiro Ikeda; Hiroshi Kataoka; Satoshi Ueno
Journal:  Am J Neurodegener Dis       Date:  2017-06-15

Review 8.  Cannabidiol and Cannabinoid Compounds as Potential Strategies for Treating Parkinson's Disease and L-DOPA-Induced Dyskinesia.

Authors:  Nilson Carlos Ferreira Junior; Maurício Dos-Santos-Pereira; Francisco Silveira Guimarães; Elaine Del Bel
Journal:  Neurotox Res       Date:  2019-10-22       Impact factor: 3.911

Review 9.  The many facets of motor learning and their relevance for Parkinson's disease.

Authors:  Lucio Marinelli; Angelo Quartarone; Mark Hallett; Giuseppe Frazzitta; Maria Felice Ghilardi
Journal:  Clin Neurophysiol       Date:  2017-04-09       Impact factor: 3.708

Review 10.  The neurobiology and neural circuitry of cognitive changes in Parkinson's disease revealed by functional neuroimaging.

Authors:  Nicola J Ray; Antonio P Strafella
Journal:  Mov Disord       Date:  2012-10-04       Impact factor: 10.338

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.